These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9607553)

  • 1. Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Urol Int; 1998; 60 Suppl 2():11-7; discussion 35. PubMed ID: 9607553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Eur Urol; 1999; 35 Suppl 1():17-21; discussion 22. PubMed ID: 10081698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study.
    Prezioso D; Lotti T; Polito M; Montironi R
    Urol Int; 2004; 72(3):189-95. PubMed ID: 15084760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
    Pu XY; Wang XH; Wu YL; Wang HP
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].
    Zierhut D
    Strahlenther Onkol; 1998 Jul; 174(7):382-3. PubMed ID: 9689961
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
    Akaza H; Homma Y; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Ohashi Y; Aso Y
    Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant hormone therapy: the Canadian trials.
    Klotz L; Gleave M; Goldenberg SL
    Mol Urol; 2000; 4(3):233-7;discussion 239. PubMed ID: 11062379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
    Rabbani F; Goldenberg SL; Klotz LH
    J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
    Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
    J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.
    Oh WK
    Urol Oncol; 2003; 21(3):229-34. PubMed ID: 12810211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.
    Bono AV; Pagano F; Montironi R; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Selli C; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Diamanti L; Santinelli A; Mazzucchelli R; Prayer-Galletti T;
    Urology; 2001 Jan; 57(1):117-21. PubMed ID: 11164155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.
    Selli C; Montironi R; Bono A; Pagano F; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Mazzucchelli R; Santinelli A;
    J Clin Pathol; 2002 Jul; 55(7):508-13. PubMed ID: 12101195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.